Researchers at a Boston biotechnology firm just released a groundbreaking study demonstrating that their new gene editing technology can significantly reduce cholesterol levels in patients at risk of heart attack and stroke.Unfortunately, discoveries like this could have been unnecessarily delayed, thanks to a decade-old Supreme Court ruling that made it harder for companies to develop these types of life-saving treatments.The case — Association for Molecular Pathology v. Myriad Genetics — was one of several that have crushed American innovation in recent years.Along with other cases, the Myriad decision confused the question of what new technologies qualify for patent protection. Without ...